Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2655-2661.
Prepublished online as a Blood First Edition Paper on June 8, 2006; DOI 10.1182/blood-2006-03-011353.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-03-011353v1
108/8/2655    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banerjee, D.
Right arrow Articles by Dhodapkar, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banerjee, D.
Right arrow Articles by Dhodapkar, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 21, 2006
Accepted June 1, 2006

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after DC injection of cytokine matured DCs in myeloma patients

Devi Banerjee, Madhav V Dhodapkar, Elyana Matayeva, Ralph M Steinman, and Kavita Dhodapkar*

Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY
Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY

* Corresponding author; email: dhodapk{at}rockefeller.edu.

CD4+CD25+FOXP3+ regulatory T cells (Tregs) play an important role in the maintenance of immune tolerance. The mechanisms controlling the induction and maintenance of Tregs in humans need to be defined. We find that human myeloid dendritic cells (DCs) are superior to other antigen presenting cells for the maintenance of FOXP3+ Tregs in culture. Co-culture of DCs with autologous T cells leads to an increase in both the number of Tregs, as well as the expression of FOXP3 protein per cell both in healthy donors and myeloma patients. DC mediated expansion of FOXP3high Tregs is enhanced by endogenous but not exogenous IL-2, and DC-T cell contact, including the CD80/86 membrane costimulatory molecules. DCs also stimulate the formation of Tregs from CD25- T cells. The efficacy of induction of Tregs by DCs depends on the nature of the DC maturation stimulus, with inflammatory cytokine treated DCs (Cyt-DC) being the most effective Treg inducers. DCs induce Tregs using cells from both healthy donors as well as myeloma patients, and the induced T regs effectively suppress T cell responses in the mixed leukocyte reaction. A single injection of Cyt-DCs led to rapid enhancement of FOXP3+ Tregs in vivo in 3/3 myeloma patients. These data reveal a role for DCs in increasing the number of functional FOXP3high Tregs in humans.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020